Memorial Sloan Kettering Cancer Center
Daily remote outcome assessments may improve symptom management during cancer treatment
Daily electronic patient-reported outcome assessments may provide valuable insight into symptom management among patients with cancer undergoing antineoplastic treatment, according to a study published in JAMA Network Open.
Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death
Memorial Sloan Kettering Cancer Center placed a pause on a phase 1 clinical trial of ATA2271 — a chimeric antigen receptor T-cell therapy — after one patient treated with the investigational therapy died.
Selinexor extends PFS in advanced endometrial cancer
Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.
Durvalumab-tremelimumab regimen significantly prolongs survival in advanced liver cancer
Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced, unresectable hepatocellular carcinoma, according to research scheduled for presentation at ASCO Gastrointestinal Cancers Symposium.
Safety measures inconsistent for opioid prescribing among older cancer survivors
Efforts should be made to increase multimodal pain management and reduce inappropriate prescribing of benzodiazepine to improve the safety of long-term opioid therapy among cancer survivors, according to results of a study in Cancer.
Polatuzumab vedotin regimen extends PFS in diffuse large B-cell lymphoma
The addition of polatuzumab vedotin to chemotherapy significantly extended PFS compared with standard first-line treatment for patients with diffuse large B-cell lymphoma, according to results presented at ASH Annual Meeting and Exposition.
Racial disparities persist among young patients with acute lymphoblastic leukemia
Considerable survival gaps exist among young white, Black and Hispanic individuals with acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.
Conversations about goals of care often occur too late in high-risk AML
Goals-of-care discussions often occur too late for patients with poor-prognosis, high-risk acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.
FDA approves Kyprolis regimen for relapsed or refractory multiple myeloma
The FDA approved a combination of carfilzomib, a subcutaneous formulation of daratumumab, and dexamethasone for certain patients with relapsed or refractory multiple myeloma.
Evolution of genetic testing for breast cancer spurs questions about best criteria to use
Genetic testing for breast cancer has evolved substantially since its inception nearly 30 years ago, according to a speaker at Chemotherapy Foundation Symposium.